

eolf-seq1
SEQUENCE LISTING

<110> PHARNEXT

<120> New compositions for treating CMT and related disorders

<130> B888PC00

<140> EP 09 305506.9

<141> 2009-06-02

<160> 14

<170> PatentIn version 3.3

<210> 1

<211> 17

<212> DNA

<213> artificial sequence

<220>

<223> forward primer_rat PMP22

<400> 1
ggaaacgcga atgaggc 17

<210> 2

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> reverse primer_rat PMP22

<400> 2
gttctgtttg gtttgctt 19

<210> 3

<211> 17

<212> DNA

<213> Artificial sequence

<220>

<223> forward primer_RPL13A

<400> 3
ctgccctcaa ggttgtg 17

<210> 4

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> reverse primer_RPL13A

<400> 4
cttcttcttc cggtaatgga t 21

<210> 5

<211> 22

<212> DNA

<213> Artificial sequence

<220>
 <223> forward primer_Pmp22-FL
 <400> 5
 gctctgagcg tgcatagggt ac 22

 <210> 6
 <211> 19
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> forward primer_ Rpl13A-FL
 <400> 6
 tcgggtggaa gtaccagcc 19

 <210> 7
 <211> 25
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> reverse primer_Pmp22-red
 <400> 7
 agggagggag gaaggaaacc agaaa 25

 <210> 8
 <211> 28
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> reverse primer_Rpl13A-red
 <400> 8
 tgacagctac tctggaggag aaacggaa 28

 <210> 9
 <211> 19
 <212> DNA
 <213> artificial sequence
 <220>
 <223> SRY - Forward
 <400> 9
 gagagaggca caagttggc 19

 <210> 10
 <211> 19
 <212> DNA
 <213> artificial sequence
 <220>
 <223> SRY - reverse
 <400> 10
 gcctcctgga aaaagggcc 19

 <210> 11

eof-seq1

<211> 19
 <212> DNA
 <213> artificial sequence

<220>
 <223> PMP22-forward

<400> 11
 tgtaccacat ccgccttgg 19

<210> 12
 <211> 22
 <212> DNA
 <213> artificial sequence

<220>
 <223> PMP22 - reverse

<400> 12
 gagctggcag aagaacagga ac 22

<210> 13
 <211> 20
 <212> DNA
 <213> artificial sequence

<220>
 <223> MPZ - forward

<400> 13
 tgttgctgct gttgctcttc 20

<210> 14
 <211> 21
 <212> DNA
 <213> artificial sequence

<220>
 <223> MPZ - reverse

<400> 14
 ttgtgaaatt tccccttctc c 21